- Generic versions of Vanda Pharmaceuticals' ( NASDAQ: VNDA ) (tasimelteon) could soon hit the market after a federal appeals court judge lifted a temporary injunction.
- The United States Court of Appeals for the Federal Circuit granted that injunction earlier in December . Teva Pharmaceutical Industries ( NYSE: TEVA ) and privately held Apotex are among generic drugmakers seeking to make cheaper copies.
- The order from the court states that "Vanda ( VNDA ) has not established that an injunction pending appeal is warranted but has shown good cause to expedite the briefing schedule."
- Vanda's ( VNDA ) deadline for providing an opening brief for the appeal is Jan. 23, 2023. Respondents' briefs are due by Feb. 27. Vanda's ( VNDA ) reply brief is due by March 9.
- A federal court previously invalidated four Hetlioz patents .
For further details see:
Federal appeals court lifts injunction barring generics of Vanda's Hetlioz